In a regulatory filing, Dr Reddy’s laboratories announced launch of Capecitabine tablets in the US.
Quoting IQVIA Health data, Dr Reddy’s said the Xeloda brand and generic had US sales of approximately USD 90 million for the most recent 12 months ending in October 2020.
Dr Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.
Shares of Dr Reddy’s Laboratories were trading 0.98 per cent lower at Rs 4,650 apiece on BSE.
Download The Economic Times News App to get Daily Market Updates & Live Business News.